Evidence map›Paper›PMID 41274959›Full record

ArticleScientific reports2025

Immune cell changes following chemotherapy in advanced pancreatic cancer with variations based on gender.

Roberto Aquilani, Salvatore Corallo, Roberto Maestri, Silvia Brugnatelli, Paolo Iadarola, Simona Viglio, Simone Figini, Beatrice Filippi, Domiziana Alaimo, Silvio Sporeni and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Roberto Aquilani *Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, Via Ferrata 9, 27100, Pavia, Italy.
Salvatore Corallo *Department of Internal Medicine and Medical Therapy, Via Ferrata 1, 27100, Pavia, Italy.
Roberto Maestri *Department of Biomedical Engineering, Istituti Clinici Scientifici Maugeri IRCCS, Scientific Institute of Montescano, 27040, Montescano, Italy.
Silvia Brugnatelli *Department of Internal Medicine and Medical Therapy, Via Ferrata 1, 27100, Pavia, Italy.
Paolo Iadarola *Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, Via Ferrata 9, 27100, Pavia, Italy.
Simona ViglioDepartment of Molecular Medicine, Biochemistry Unit, University of Pavia, Viale T. Taramelli 3, 27100, Pavia, Italy.
Simone FiginiDepartment of Internal Medicine and Medical Therapy, Via Ferrata 1, 27100, Pavia, Italy.
Beatrice FilippiDepartment of Internal Medicine and Medical Therapy, Via Ferrata 1, 27100, Pavia, Italy.
Domiziana AlaimoDepartment of Internal Medicine and Medical Therapy, Via Ferrata 1, 27100, Pavia, Italy.
Silvio SporeniDepartment of Internal Medicine and Medical Therapy, Via Ferrata 1, 27100, Pavia, Italy.
Manuela VerriDepartment of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, Via Ferrata 9, 27100, Pavia, Italy.
Federica BoschiDepartment of Drug Sciences, University of Pavia, Viale T. Taramelli, 14, 27100, Pavia, Italy. federica.boschi@unipv.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To explore the changes in blood inflammatory cells (neutrophils, monocytes, platelets) and adaptive immune cells (lymphocytes) during chemotherapy, we retrospectively analysed medical records from 66 patients with unresectable Pancreatic Ductal Adenocarcinoma (PDAC) treated with the Gemcitabine-nab-Paclitaxel (GnP) regimen. Evaluations were conducted at baseline (pre-GnP, TA), after the first cycle (TB), and after the third cycle (TC) of treatment. In metastatic PDAC (mPDAC), the monocyte-to-lymphocyte ratio significantly increased at both TB and TC compared to TA, whereas no such change was observed in locally advanced PDAC (laPDAC) (interaction: p = 0.006). Platelet levels rose over time in both phenotypes, with a more pronounced increase in mPDAC (intergroup: p = 0.008). When stratified by gender, males with mPDAC showed an increase in monocyte percentages among total white blood cells (intergroup: p = 0.018), while both phenotypes exhibited rising platelet-to-lymphocyte ratios over time. In females, the platelet-to-lymphocyte ratio increased more significantly in laPDAC than in mPDAC (interaction: p = 0.046). GnP treatment notably increased circulating inflammatory cells and their relationships with lymphocytes in a manner dependent on both disease phenotype and gender. Pretreatment factors such as monocyte counts < 0.6 × 10

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalPancreatic NeoplasmsAdultAgedAged, 80 and overAlbuminsBlood PlateletsDeoxycytidineFemaleGemcitabineHumansLymphocytesMaleMiddle AgedMonocytes130-nm albumin-bound paclitaxelAlbuminsDeoxycytidineGemcitabinePaclitaxelChemotherapy changes in circulating immune cellsGenderPancreatic cancerPredictors of survival

Identifiers

PMID41274959
PMCPMC12658210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.